NewsRoom Articles - Page 54 of 57 - PsychedelicNewsWire (PNW)

ThursdayOct 12, 2017 9:30 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral Digestion Technology Needs No Sugar Coating

Delivery technology with application to all non-psychoactive cannabinoids Company is an enabler rather than competitor to hemp oil producers Revenue from licensing DehydraTECH oral digestion technology Thanks to Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), there’s no need for a spoonful of sugar to help the medicine go down. This innovative biotech has developed technology that masks the strong taste and odor of hemp oil products, eschewing the need for artificial sweeteners, which tend to come with their own fallout to heart and health. Lexaria’s DehydraTECH oral digestion technology is a ‘back office’ process that solves the taste and odor…

TuesdayOct 10, 2017 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Bioabsorption Tech Boosting Development of CBD Products

Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products Patents have been awarded in the U.S. and Australia and are pending in 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology…

TuesdayOct 03, 2017 9:00 am

Cannabis Market Extends across Numerous Industry Segments

PsychedelicNewsWire Editorial Coverage: Growth has been the dominant theme in the cannabis market. Estimates by Forbes put the legal cannabis market at a value of $7.2 billion (per a February 2017 report), and the market is expected to generate more jobs than government, manufacturing, or utilities in the coming years, according to the Bureau of Labor Statistics. Numerous industries are being impacted. Cultivation and medicine are just a couple of examples, but cannabis is showing a strong presence in the retail, consulting, and consumer sectors. SinglePoint, Inc. (SING) (SING Profile) has focused on business development in multiple segments thanks to…

FridaySep 29, 2017 12:52 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event

Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins Growing portfolio of intellectual property includes 19 patents filed across 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is…

WednesdaySep 27, 2017 1:14 pm

Grey Cloak Tech Inc. (GRCK) Signs Letter of Intent to Acquire Eqova Life Sciences

Clinical-grade full spectrum hemp oil products created for licensed medical practitioners included Science-backed education, superior products meet requirements of medical profession Medical cannabinoid product revenue projected to reach $1.15 billion by 2020 Grey Cloak Tech Inc. (OTC: GRCK) recently announced that it has signed a binding Letter of Intent to purchase Eqova Life Sciences, a California-based medically-focused company producing clinical-grade full spectrum hemp oil products. To date, no other hemp oil company has exclusively focused on the medical practitioner market, leaving this important segment largely underserved. Grey Cloak Tech, which is known for its click fraud prevention products, has been…

MondaySep 25, 2017 1:45 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets

Technology that improves bio-absorption and bio-availability Bioactive compound delivery system with application across a range of drugs Revenue streams from out-licensing The word in culinary circles is that where there is fat, there is flavor. That’s because fats (there are several different kinds) have a matchless ability to absorb and preserve flavors. Fats belong to a class of compounds called lipids, which the human digestive system absorbs remarkably efficiently. This characteristic makes them ideal for pairing with hard to digest remedials and tonics. Taking a leaf, perhaps, from haute cuisine, this is exactly what Lexaria Bioscience Corp. (CSE: LXX) (OTCQB:…

WednesdaySep 13, 2017 3:58 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract,…

TuesdaySep 12, 2017 3:55 pm

Algae Dynamics Corp. (ADYNF) Collaborating with Prominent Neuroscientist to Research Benefits of Cannabis Oil for Mental Health Disorders

Partnership between Algae Dynamics and Dr. Steven Laviolette focuses on medical benefits of cannabis and hemp oils for various mental health disorders Canada is moving to legalize cannabis throughout the country in 2018, which could radically change research playing field Canadian cannabis oil extraction market projected to reach $1.5 billion by 2020 Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company focused on the development of proprietary research and products derived from cannabis and hemp oils, has begun a collaborative relationship with one neuroscientist who is looking deep within the brain for answers to some of the world’s most pressing mental…

FridayAug 25, 2017 9:23 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

ThursdayAug 24, 2017 3:22 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Licensed to Grow Cannabis by Feds in Canada

An early mover in the Canadian cannabis space Serving Canada’s most populous province New funding deal signed for $15 million at $2.25 per share As befits its status as a first mover in the Canadian cannabis space, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) is racing ahead with plans to supply the medical marijuana needs of Canada’s most populous province. Construction plans at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot phase 1 project have been expanded to 100,000 square feet. The company recently signed a…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050